Xenon Pharmaceuticals Inc. (XENE) Statistics & Valuation Metrics - Stocknear

Xenon Pharmaceuticals Inc...

NASDAQ: XENE · Real-Time Price · USD
36.42
-0.80 (-2.15%)
At close: Sep 12, 2025, 3:32 PM

Xenon Pharmaceuticals Statistics

Share Statistics

Xenon Pharmaceuticals has 77.11M shares outstanding. The number of shares has increased by 1.28% in one year.

77.11M
1.28%
0.25%
94.47%
74.01M
27,706
2.57%

Short Selling Information

The latest short interest is 6.89M, so 8.94% of the outstanding shares have been sold short.

6.89M
8.94%
9.97%
5.71

Valuation Ratios

The PE ratio is -13.03 and the forward PE ratio is -8.07. Xenon Pharmaceuticals's PEG ratio is -1.27.

-13.03
-8.07
0
146.7
4.04
-16.55
-1.27
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Xenon Pharmaceuticals.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 17.85, with a Debt / Equity ratio of 0.01.

17.85
17.85
0.01
-0.04
-0.05
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-741.55K
316
0
n/a

Taxes

-4.09M
1.72%

Stock Price Statistics

The stock price has increased by -5.46% in the last 52 weeks. The beta is 1.17, so Xenon Pharmaceuticals's price volatility has been higher than the market average.

1.17
-5.46%
34.76
35.85
51.57
1,077,920

Income Statement

n/a
-2.56M
-279.3M
-234.33M
-235.86M
-238.42M
-3.01
Full Income Statement

Balance Sheet

The company has 142.71M in cash and 9.02M in debt, giving a net cash position of 133.7M.

142.71M
9.02M
133.7M
-899.47M
674.28M
467.2M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -181.39M and capital expenditures -3.08M, giving a free cash flow of -184.46M.

-181.39M
-3.08M
-184.46M
-2.37
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

XENE does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for XENE is $54, which is 45.1% higher than the current price. The consensus rating is "Buy".

$54
45.1%
Buy
10
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

39.99
2